Hypermarcas (OTCMKTS:HYPMY) Raised to “Strong-Buy” at Jefferies Financial Group

Hypermarcas (OTCMKTS:HYPMY) was upgraded by equities researchers at Jefferies Financial Group to a “strong-buy” rating in a research note issued to investors on Monday,Zacks.com reports.

Separately, Zacks Research upgraded Hypermarcas to a “hold” rating in a report on Wednesday, April 29th. One analyst has rated the stock with a Strong Buy rating and one has assigned a Hold rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Buy”.

Hypermarcas Price Performance

Shares of HYPMY stock opened at $4.04 on Monday. Hypermarcas has a fifty-two week low of $3.71 and a fifty-two week high of $5.50. The stock’s 50-day moving average is $4.18 and its two-hundred day moving average is $4.39. The firm has a market cap of $2.84 billion, a P/E ratio of 8.41 and a beta of 0.71.

Hypermarcas (OTCMKTS:HYPMY) last posted its quarterly earnings results on Wednesday, April 29th. The company reported $0.10 earnings per share for the quarter. The company had revenue of $383.13 million during the quarter. Hypermarcas had a return on equity of 14.08% and a net margin of 19.41%. As a group, research analysts expect that Hypermarcas will post 0.53 EPS for the current year.

About Hypermarcas

Hypermarcas SA is a Brazil-based consumer health and pharmaceutical company whose shares trade over the counter in the United States under the symbol HYPMY. Founded in the early 2000s and headquartered in Rio de Janeiro, the company operates as a holding group for a broad portfolio of branded products in the healthcare and personal care sectors.

Through its various subsidiaries, Hypermarcas develops, manufactures and markets prescription and over-the-counter medications, alongside personal care, baby care, home care and nutritional supplement products.